Cholesterol emboli syndrome causes

Revision as of 20:16, 31 January 2021 by NNikravangolsefid (talk | contribs)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search

Cholesterol emboli syndrome Microchapters

Home

Overview

Historical Perspective

Pathophysiology

Causes

Differentiating Cholesterol emboli syndrome from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Cholesterol emboli syndrome causes On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Cholesterol emboli syndrome causes

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Cholesterol emboli syndrome causes

CDC on Cholesterol emboli syndrome causes

Cholesterol emboli syndrome causes in the news

Blogs on Cholesterol emboli syndrome causes

Directions to Hospitals Treating Cholesterol emboli syndrome

Risk calculators and risk factors for Cholesterol emboli syndrome causes

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Nasrin Nikravangolsefid, MD-MPH [2]

Overview

Common causes of Cholesterol emboli syndrome (CES) include spontaneously due to atherosclerosis of the large arteries and iatrogenic secondary to medical interventions such as vascular surgery or angiography. Less common causes of CES include intake of anticoagulants such as warfarin or thrombolytic medications.

Causes


References

  1. Fukumoto, Yoshihiro; Tsutsui, Hiroyuki; Tsuchihashi, Miyuki; Masumoto, Akihiro; Takeshita, Akira (2003). "The incidence and risk factors of cholesterol embolization syndrome, a complication of cardiac catheterization: a prospective study". Journal of the American College of Cardiology. 42 (2): 211–216. doi:10.1016/S0735-1097(03)00579-5. ISSN 0735-1097.
  2. Ramirez, German (1978). "Cholesterol Embolization". Archives of Internal Medicine. 138 (9): 1430. doi:10.1001/archinte.1978.03630340096035. ISSN 0003-9926.
  3. Feder, Walter (1961). ""Purple Toes": an Uncommon Sequela of Oral Coumarin Drug Therapy". Annals of Internal Medicine. 55 (6): 911. doi:10.7326/0003-4819-55-6-911. ISSN 0003-4819.
  4. Shapiro LS (1989). "Cholesterol embolization after treatment with tissue plasminogen activator". N Engl J Med. 321 (18): 1270. doi:10.1056/NEJM198911023211816. PMID 2507919.

Template:WikiDoc Sources